文献速递肿瘤 PET/CT核素与放射性配体治疗

成纤维细胞激活蛋白抑制剂PET/CT在泌尿生殖系统肿瘤中诊断价值的系统评价

A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers.
PubMed 文献 · J Nucl Med · 2024-06-03

该系统评价依据PRISMA流程检索Embase和Medline,纳入22项回顾性研究共69例患者,评估FAPI PET/CT在前列腺癌、尿路上皮癌、肾细胞癌和睾丸癌中的诊断价值。FAPI PET/CT可显示局部和转移病灶,与18F-FDG和PSMA PET/CT比较表现不一。作者认为FAPI PET/CT可能是有前景的未来工具,但因研究间异质性大且患者数有限,解读需谨慎。

要点

  • 纳入22项回顾性研究共69例患者,聚焦前列腺癌、膀胱及上尿路尿路上皮癌、肾细胞癌和睾丸癌。
  • FAPI PET/CT可显示局部和转移病灶,包括PSMA阴性前列腺癌等疑难病例。
  • 与18F-FDG和PSMA PET/CT比较表现不一,部分病例肿瘤显像优于18F-FDG PET/CT。

核心结论

  • 当前发现提示FAPI PET/CT可能作为未来帮助临床医生检测泌尿生殖系统恶性肿瘤的工具。
  • 鉴于纳入研究间存在显著异质性且患者数量有限,解读这些发现需谨慎。
  • 后续前瞻性和对比性研究有望深入探索这一创新影像模式并阐明其在临床实践中的作用。

研究设计与样本

  • 系统评价,于2023年8月1日依据PRISMA流程检索Embase和Medline。
  • 纳入报告FAPI PET/CT在泌尿生殖系统恶性肿瘤中诊断价值的相关文献。
  • 采用病例报告质量评价工具的修改版对研究进行批判性审阅,并以叙述性方法汇总结果。
  • 共纳入22项回顾性研究,累计69例患者。

主要发现

  • FAPI PET/CT能够显示局部和转移性疾病,包括PSMA阴性前列腺癌等疑难病例。
  • 与放射性标记的18F-FDG和PSMA PET/CT相比,FAPI PET/CT表现出异质性。
  • 在部分选定病例中,FAPI PET/CT检测局部或转移性疾病时肿瘤显像优于18F-FDG PET/CT,即更好的靶本比以及显示其他方式无法可见的小肿瘤或转移灶。
  • 与PSMA PET/CT的比较则显示既有优也有劣的表现。
  • 多数FAPI放射性药物的生理性泌尿排泄妨碍膀胱和上尿路原发灶显像,尽管通常提供高靶本比。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 纳入研究间存在显著异质性。
  • 患者数量有限。
  • 纳入的研究均为回顾性研究。
  • 多数FAPI放射性药物的生理性泌尿排泄妨碍膀胱和上尿路原发灶显像。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In contemporary oncologic diagnostics, molecular imaging modalities are pivotal for precise local and metastatic staging. Recent studies identified fibroblast activation protein as a promising target for molecular imaging across various malignancies. Therefore, we aimed to systematically evaluate the current literature on the utility of fibroblast activation protein inhibitor (FAPI) PET/CT for staging patients with genitourinary malignancies. Methods: A systematic Embase and Medline search was conducted, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) process, on August 1, 2023. Relevant publications reporting on the diagnostic value of FAPI PET/CT in genitourinary malignancies were identified and included. Studies were critically reviewed using a modified version of a tool for quality appraisal of case reports. Study results were summarized using a narrative approach. Results: We included 22 retrospective studies with a cumulative total of 69 patients, focusing on prostate cancer, urothelial carcinoma of the bladder and of the upper urinary tract, renal cell carcinoma, and testicular cancer. FAPI PET/CT was able to visualize both local and metastatic disease, including challenging cases such as prostate-specific membrane antigen (PSMA)-negative prostate cancer. Compared with radiolabeled 18F-FDG and PSMA PET/CT, FAPI PET/CT showed heterogeneous performance. In selected cases, FAPI PET/CT demonstrated superior tumor visualization (i.e., better tumor-to-background ratios and visualization of small tumors or metastatic deposits visible in no other way) over 18F-FDG PET/CT in detecting local or metastatic disease, whereas comparisons with PSMA PET/CT showed both superior and inferior performances. Challenges in FAPI PET/CT arise from physiologic urinary excretion of most FAPI radiotracers, hindering primary-lesion visualization in the bladder and upper urinary tract, despite generally providing high tumor-to-background ratios. Conclusion: The current findings suggest that FAPI PET/CT may hold promise as a future tool to aid clinicians in detecting genitourinary malignancies. Given the substantial heterogeneity among the included studies and the limited number of patients, caution in interpreting these findings is warranted. Subsequent prospective and comparative investigations are anticipated to delve more deeply into this innovative imaging modality and elucidate its role in clinical practice.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hagens MJ, van Leeuwen PJ, Wondergem M, et al. A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers. J Nucl Med. 2024. PMID: 38637140. doi:10.2967/jnumed.123.267260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。